AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

DSV

Transaction in Own Shares Mar 8, 2022

3363_dirs_2022-03-08_61be92c8-1c63-4eb4-9b72-0025f58e065b.html

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

DSV, 948 - SHARE BUYBACK IN DSV A/S

DSV, 948 - SHARE BUYBACK IN DSV A/S

Company Announcement No. 948

On 9 February 2022, we initiated a share buyback programme, as described in Company Announcement No. 942. According to the programme, the company will in the period from 9 February 2022 to 26 April 2022 may purchase own shares up to a maximum value of DKK 2,500 million and no more than 2,500,000 shares, corresponding to 1.04% of the current share capital of DSV A/S. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.

Trading day Number of shares bought back Average transaction price Amount DKK
Accumulated trading for days 1-13 799,000 1,235.07 986,823,740
14: 28 February 2022 26,000 1,210.19 31,464,940
15: 1 March 2022 80,000 1,206.53 96,522,400
16: 2 March 2022 50,000 1,207.92 60,396,000
17: 3 March 2022 15,000 1,211.81 18,177,150
18: 4 March 2022 85,000 1,204.55 102,386,750
Accumulated trading for days 1-18 1,055,000 1,228.22 1,295,770,980

After the disclosed transactions, DSV A/S holds a total of 7,618,991 shares of a nominal value of DKK 1 in DSV A/S, corresponding to 3.17% of the total number of issued shares of 240,000,000.

The details of each transaction made under the share buyback programme are published on investor.dsv.com.

Any questions may be addressed to Executive Vice President, Investor Relations, Flemming Ole Nielsen, tel. +45 43 20 33 92.

Yours sincerely,

DSV A/S

Attachment

Talk to a Data Expert

Have a question? We'll get back to you promptly.